Key Points
- Director Jack Wyszomierski sold 99,574 shares on February 18 at an average price of $44.01 for $4.38M, reducing his stake by 26.24% to 279,942 shares (valued ~ $12.32M).
- Quarterly results beat on EPS ($0.94 vs. $0.74 consensus) but revenue missed ($598.66M vs. $609.17M); the stock trades around $43.63 with a market cap of $11.33B and a 12‑month range of $32.38–$49.62.
- Institutional ownership is high at 85.27% with several funds increasing positions (e.g., Goldman Sachs), while analyst coverage is mixed — average rating "Hold" and average target $47.11.
Exelixis, Inc. (NASDAQ:EXEL - Get Free Report) Director Jack Wyszomierski sold 99,574 shares of the firm's stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $44.01, for a total value of $4,382,251.74. Following the completion of the sale, the director directly owned 279,942 shares in the company, valued at $12,320,247.42. This trade represents a 26.24% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
Exelixis Trading Down 1.2%
Shares of NASDAQ EXEL opened at $43.63 on Friday. The company has a market cap of $11.33 billion, a price-to-earnings ratio of 15.75, a PEG ratio of 0.99 and a beta of 0.42. Exelixis, Inc. has a 12 month low of $32.38 and a 12 month high of $49.62. The stock has a 50-day moving average price of $43.88 and a two-hundred day moving average price of $41.20.
Exelixis (NASDAQ:EXEL - Get Free Report) last posted its quarterly earnings results on Tuesday, February 10th. The biotechnology company reported $0.94 earnings per share for the quarter, beating analysts' consensus estimates of $0.74 by $0.20. The company had revenue of $598.66 million for the quarter, compared to the consensus estimate of $609.17 million. Exelixis had a net margin of 33.73% and a return on equity of 36.29%. The firm's quarterly revenue was up 5.6% compared to the same quarter last year. During the same period last year, the company posted $0.55 EPS. On average, sell-side analysts predict that Exelixis, Inc. will post 2.04 earnings per share for the current year.
Institutional Investors Weigh In On Exelixis
Several institutional investors and hedge funds have recently made changes to their positions in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Exelixis by 81.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,181 shares of the biotechnology company's stock worth $1,592,000 after acquiring an additional 19,407 shares during the last quarter. Goldman Sachs Group Inc. increased its position in Exelixis by 4.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,466,779 shares of the biotechnology company's stock valued at $54,153,000 after purchasing an additional 68,133 shares during the period. Focus Partners Wealth raised its holdings in Exelixis by 83.4% during the 1st quarter. Focus Partners Wealth now owns 38,458 shares of the biotechnology company's stock worth $1,420,000 after purchasing an additional 17,483 shares during the last quarter. Geneos Wealth Management Inc. lifted its position in shares of Exelixis by 134.3% in the 1st quarter. Geneos Wealth Management Inc. now owns 1,647 shares of the biotechnology company's stock worth $61,000 after purchasing an additional 944 shares during the period. Finally, Sivia Capital Partners LLC boosted its stake in shares of Exelixis by 23.8% in the 2nd quarter. Sivia Capital Partners LLC now owns 14,362 shares of the biotechnology company's stock valued at $633,000 after purchasing an additional 2,764 shares during the last quarter. Institutional investors and hedge funds own 85.27% of the company's stock.
Analyst Ratings Changes
EXEL has been the subject of several research analyst reports. Zacks Research upgraded shares of Exelixis from a "hold" rating to a "strong-buy" rating in a report on Wednesday, February 4th. Citigroup lowered Exelixis from a "market outperform" rating to an "underperform" rating in a research report on Monday, January 5th. HC Wainwright upped their target price on Exelixis from $52.00 to $54.00 and gave the stock a "buy" rating in a report on Thursday, February 12th. Weiss Ratings reissued a "buy (b)" rating on shares of Exelixis in a research note on Thursday, January 22nd. Finally, Morgan Stanley upped their price objective on Exelixis from $48.00 to $49.00 and gave the company an "equal weight" rating in a research note on Monday, February 2nd. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, ten have issued a Hold rating and two have issued a Sell rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Hold" and an average target price of $47.11.
View Our Latest Stock Report on EXEL
Exelixis Company Profile
(
Get Free Report)
Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis's translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.
The company's most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
